2007/01/04 by Bryan L. Roth · 2 citations
Medicine · #Pharmacology and Obesity Treatment #Hormonal and reproductive studies #Cardiovascular Syncope and Autonomic Disorders
paper · doi:10.1056/nejmp068265
openalex publication_date 2007/01/04 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
In 1997, Connolly et al. reported that both racemic fenfluramine (Pondimin) and dexfenfluramine (Redux) were associated with valvular heart disease.1 The valvular abnormalities seen in patients treated with these agents were distinctive. On echocardiography, leaflet thickening as well as chordal thickening and retraction were observed. Surgically removed valves were noted to have a glistening white surface, with histologic evidence of a plaque-like process extending along the leaflet surfaces and encasing the chordae tendineae. These findings were similar to those in patients with heart-valve damage induced by serotonin-secreting carcinoid tumors.1 This association of racemic fenfluramine and dexfenfluramine with valvular heart disease . . .